Site
Client
proxystylesheet
Output
Search
allAreas
However, we recognize that organizations face a number of hurdles in realizing these benefits due to the lack of trustworthy biomarkers data and standards in the public domain.
By drawing on the experience and knowledge of scientists in Prous Science, a Thomson Reuters business, as well as extensive participation of external experts, Thomson Reuters is uniquely placed to establish and develop these standards, and to provide trusted, authoritative biomarker information.
To find out more on BIOMARKERcenter and to receive complimentary copies of our Biomarkers Pharma Matters White Papers, please complete the form below.
*Indicates required field
Biomarkers: An indispensable addition to the drug development toolkit
Establishing the standards in biomarkers research
In this white paper, we explore the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents. The potential of biomarkers to improve decision making, accelerate drug development and reduce development costs is discussed with insight from experts in industry and academia.
In this white paper, we show how the pharmaceutical industry is already beginning to rely on biomarker information, and explain how important it is to establish the standards that will support increasing biomarker implementation in the future.
The Scientific business of Thomson Reuters would like to keep you up to date with developments to our products and services. We would also like to invite you to special events such as seminars and receptions, and we would like you to benefit from our free newsletters and other resources.
Find out more about the Scientific business of Thomson Reuters.
For information about our privacy policies or to change your communications preferences, please refer to our Privacy Statement.
